LY3509754

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

HealthyPsoriasis

Phase 1

A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

TerminatedNCT04152382

Eli Lilly and CompanyPsoriasis

Start: 2019-11-20End: 2022-02-09Updated: 2022-03-15

A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants

TerminatedNCT04586920

Eli Lilly and CompanyHealthy

Start: 2020-10-20End: 2022-10-14Updated: 2025-01-03

Related Papers

Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of <scp>IL‐17A</scp> (<scp>LY3509754</scp>): A Phase I Randomized Placebo‐Controlled Study

Clinical Pharmacology & Therapeutics2024-01-3123 citations